Teva Pharmaceutical Industries (TEVA) Buildings (2009 - 2025)

Teva Pharmaceutical Industries has disclosed Buildings across 17 years of filings, most recently posting $2.3 billion for Q4 2025.

• Quarterly Buildings rose 18.24% year-over-year to $2.3 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 18.24% YoY) and the FY2025 annual result came in at $2.3 billion, up 18.24% from the prior year.
• Buildings climbed to $2.3 billion in Q4 2025, from $2.0 billion in the prior quarter.
• Over five years, Buildings peaked at $2.6 billion in Q4 2021 and troughed at $2.0 billion in Q4 2024.
• A 5-year average of $2.4 billion and a median of $2.5 billion in 2022 frame the typical range for Buildings.
• Annual changes were most pronounced in 2024 — Buildings decreased 20.9% — and 2025, when it grew 18.24%.
• Tracing TEVA's Buildings over 5 years: stood at $2.6 billion in 2021, then fell by 4.09% to $2.5 billion in 2022, then gained by 1.02% to $2.5 billion in 2023, then fell by 20.9% to $2.0 billion in 2024, then grew by 18.24% to $2.3 billion in 2025.
• Business Quant data shows TEVA's Buildings at $2.3 billion in Q4 2025, $2.0 billion in Q4 2024, and $2.5 billion in Q4 2023.